Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical Japan India

Indian Aurobindo Readies API Factory For Japanese Market

This article was originally published in PharmAsia News

Executive Summary

Amid a wave of Indian pharmaceutical makers increasing exports to Japan, Aurobindo Pharma Ltd is getting ready to commence operations of its new active ingredient plant that is wholly devoted to the Japanese market.

Amid a wave of Indian pharmaceutical makers increasing exports to Japan, Aurobindo Pharma Ltd is getting ready to commence operations of its new active ingredient plant that is wholly devoted to the Japanese market. The Hyderabad-based firm plans to start operating the state-of-art API facility at the end of March. Aurobindo is streamlining its operations to meet particular needs of its Japanese customers, and products with Japanese quality and Indian prices will gain market share in Japan, Aurobindo expects. (Click here for more – Japanese language)

“AuroBindo Of India Completes Special API Plant” – Chemical Daily (3/21/2012)

Table

View full table

Topics

Tags:
BioPharmaceutical Japan India
Latest Headlines

Xaira Launches With $1bn-Plus And End-To-End AI Strategy

Biogen Sees Improving Momentum In Slow Leqembi Launch

Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative

Day One Springs Into Commercial Action With Ojemda Approval

See All
UsernamePublicRestriction

Register

SC080622

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By